EcoR1 Capital, LLC - Mar 8, 2024 Form 3 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Role
10%+ Owner
Signature
/s/ Oleg Nodelman, Manager of EcoR1 Capital, LLC
Stock symbol
ADAP
Transactions as of
Mar 8, 2024
Transactions value $
$0
Form type
3
Date filed
3/26/2024, 12:00 PM
Previous filing
Dec 28, 2023
Next filing
Aug 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ADAP Ordinary Shares 164M Mar 8, 2024 See Note F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These Ordinary Shares are held through 27,404,070 American Depository Shares, each representing 6 Ordinary Shares.
F2 The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and Oleg Nodelman. EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself and the other reporting person. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 3d-5(b) under the Securities and Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
F3 Qualified Fund beneficially owns 155,106,660 Ordinary Shares.